Dr. David D. Shepard, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 177
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Indiana University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 066068 -
Specialist
GA license 66068
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Kennestone Regional Medical Center Marietta, GA
- Wellstar Cobb Medical Center Austell, GA
- Wellstar PAulding Medical Center Hiram, GA
- Wellstar Douglas Medical Center Douglasville, GA
Medical groups
- Wellstar Medical Group LLC (3,093 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 177
- Services billed
- 523
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 102 | 50 |
| New patient office or other outpatient visit, 45-59 minutes | 50 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 40 | 31 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Decatur, GA | 93 |
| Eliquis (apixaban) Other prescribers in Decatur, GA | 70 |
| Mirtazapine Other prescribers in Decatur, GA | 37 |
| Dexamethasone Other prescribers in Decatur, GA | 37 |
| Gabapentin Other prescribers in Decatur, GA | 36 |
| Prochlorperazine Maleate Other prescribers in Decatur, GA | 30 |
| Ondansetron Hcl Other prescribers in Decatur, GA | 26 |
| Oxycodone Hcl Other prescribers in Decatur, GA | 19 |
| Duloxetine Hcl Other prescribers in Decatur, GA | 18 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Decatur, GA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 48 companies reported 152 payments worth $4,760 in total to this clinician.
| Food and Beverage | $3,535 |
|---|---|
| Long term medical supply or device loan | $1,000 |
| Education | $226 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc Feb 14, 2025 | Education in-kind | $99.99 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Pfizer Inc. Oct 30, 2025 | Education TUKYSA · ONCOLOGY · in-kind | $16.01 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Janssen Biotech, Inc. Jun 18, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $77.99 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP May 5, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Sobi, Inc Feb 14, 2025 | Education in-kind | $99.99 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Education LYNPARZA · Oncology · in-kind Company’s descriptionEducational Item | $8.65 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.